JCR Pharmaceuticals Co., Ltd. (“JCR”) has implemented a Named Patient Supply Program for IZCARGO® for I.V. infusion 10mg (“IZCARGO®” JAN: Pabinafusp Alfa (Genetical Recombination)) for patients with Mucopolysaccharidosis type II (MPS II or Hunter syndrome).
The Named Patient Supply Program will enable early access to IZCARGO® for eligible patients in certain countries where it is not commercially available yet. IZCARGO® is currently only approved in Japan. JCR has signed an agreement with Clinigen to implement the Named Patient Supply Program. Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.